Answers are grounded in this paper and cite their sources.
Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.
No takes yet. Share an insight, caveat, or question.
Stephen B. Hanauer (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: